EU Joint Programme - Neurodegenerative Disease Research

EU Joint Programme on Neurodegenerative Disease Research (JPND)

Path: /organizations/jpnd Type: Intergovernmental Research Initiative / Funding Mechanism Location: Brussels, Belgium (coordinated across 30+ countries) Founded: 2009 (EU commission; first calls 2011) Website: [neurodegenerationresearch.eu](https://www.neurodegenerationresearch.eu) Participating Countries: 30+ EU member states and associated countries

Overview

EU Joint Programme on Neurodegenerative Disease Research (JPND)

Path: /organizations/jpnd Type: Intergovernmental Research Initiative / Funding Mechanism Location: Brussels, Belgium (coordinated across 30+ countries) Founded: 2009 (EU commission; first calls 2011) Website: [neurodegenerationresearch.eu](https://www.neurodegenerationresearch.eu) Participating Countries: 30+ EU member states and associated countries

Overview

The Joint Programme on Neurodegenerative Disease Research (JPND) is the largest European research initiative focused on neurodegenerative diseases, established in 2009 by the European Commission and national research funding agencies across 30+ countries. JPND coordinates national research funding to address the growing challenge of Alzheimer's disease, [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), [frontotemporal dementia](/diseases/frontotemporal-dementia), [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), and related disorders["@jpnd2024"][@jpnd2012].

Unlike traditional funding mechanisms, JPND operates as a "meta-funding" body — coordinating calls for transnational research proposals where multiple national agencies co-fund the same project. This approach avoids duplication and maximizes impact by enabling large-scale, cross-border collaborations that no single national program could support alone["@alachkar2021"].

Mission and Objectives

JPND's mission is to coordinate national research efforts to:

Strategic Priorities (2024-2030)

JPND's current strategy emphasizes[@alzheimer2024]:

• Harmonized data standards: Cross-national interoperability of patient data
• Cohort linkage: Connecting existing national cohorts for pan-European analyses
• Biomarker standardization: Validated fluid and imaging biomarkers across sites
• Patient involvement: Embedding patient perspectives in research design
• Industry engagement: Facilitating pharma/biotech participation in public-private projects

Funding Model

Joint Transnational Calls

JPND's core mechanism is issuing joint transnational calls where:

• Multiple countries participate in the same funding call
• Research consortia include partners from at least 3 participating countries
• Each national agency funds its own research team
• Consortia share data, methodologies, and biological samples

Funding Scale

• Typical JPND calls fund 5-15 consortia
• Total budget per call: €20-50 million
• Individual project funding: €1-5 million over 3-4 years
• Over 1 billion EUR invested since 2011

Call Topics

Recent JPND calls have addressed:

• Harmonized assessment of prodromal Alzheimer's (2023)
• Sex and gender differences in neurodegenerative disease (2022)
• Digital biomarkers for early detection (2021)
• Links between peripheral and CNS mechanisms (2020)
• Large-scale analysis of existing cohorts (2019)
• Innovative treatment approaches (2018)
• Biomarkers for disease modification (2016)

Key Research Programs

Cohorts and Biobanks

JPND has invested heavily in harmonizing existing European cohorts[@burnham2021]:

• European ADNI (E-ADNI): Harmonized Alzheimer's disease imaging data
• LIDINA: Longitudinal studies on inflammatory mechanisms
• PROXIMA: Biomarker cross-validation across sites
• BIOMARKAPD: Blood-based biomarker standardization for AD and PD

Data Sharing Infrastructure

JPND has developed:

• Harmonized metadata standards for neurodegeneration cohorts
• Cross-national data access procedures enabling researchers to request data from multiple countries
• Common data model for cohort interoperability
• Ethical framework for transnational data sharing[@hamilton2023]

Biobank Coordination

JPND supports:

• Standard operating procedures for brain tissue and biofluid handling
• Virtual biobank connecting 30+ national biobanks
• Quality assurance programs for sample integrity
• Cross-border sample transfer protocols[@gaveriaux-roehrig2023]

European Country Participation

JPND includes national funding agencies from 30+ countries:

| Country | Funding Agency | ND Research Focus |
|---------|----------------|-------------------|
| Germany | DFG, BMBF | AD, PD, ALS, FTD |
| France | ANR, INSERM | Tauopathies, ALS |
| UK | MRC, NIHR | AD, PD, MND |
| Italy | MIUR | Neuroinflammation |
| Spain | ISCIII | Aging and dementia |
| Sweden | VR, FORMAS | PD, protein aggregation |
| Netherlands | ZonMw | Biomarkers, clinical trials |
| Belgium | FWO, FRS | Neurodegeneration mechanisms |
| Austria | FWF | Basic science |
| Switzerland | SNSF | PD, AD, rare diseases |
| Denmark | Danish Council | Biomarkers |
| Norway | RCN | Population-based studies |
| Finland | Academy | Neuroinflammation |
| Ireland | SFI, HRB | Clinical research |
| Poland | NCBR, NCN | Genetics |
| Czech Republic | GA CR | Basic mechanisms |
| Hungary | NKFI | Clinical cohorts |

Connection to PSP Research

JPND supports PSP-related research through:

Research Priorities for PSP

Within JPND's broader neurodegeneration framework, areas particularly relevant to PSP include:

• 4R-tau isoform biology and selective vulnerability
• Fluid biomarkers for PSP diagnosis and progression monitoring
• Imaging endpoints for clinical trials (tau PET, MRI)
• Genetic risk factors for sporadic and familial PSP
• Natural history studies across European populations
• Trial readiness infrastructure for upcoming therapeutic trials

Impact and Achievements

Major Outputs

JPND-funded research has produced:

Notable Projects

• PRODEMOS: Precision prevention in dementia using lifestyle and medical interventions
• EPAD: European Prevention for Alzheimer's Disease longitudinal cohort
• EPAPP: Alzheimer's Prevention clinical trials platform
• MIRAGE: Multi-arm trials for neuroprotection

How to Apply

For Researchers

JPND calls are announced annually, typically with:

• Application deadline: Autumn (September-October)
• Review period: 6-9 months
• Funding start: Following year

Consortium Requirements

• Minimum 3 countries from JPND participating list
• Balanced participation across partner countries
• Clear data sharing plan
• Patient and public involvement strategy

Next Steps

Researchers should:

Cross-References

• [National Institute on Aging](/institutions/nih-nia)
• [NIH NINDS](/institutions/nih-ninds)
• [UK Dementia Research Institute](/institutions/uk-dementia-research-institute)
• [European Research Council](/institutions/european-research-council)
• [CurePSP](/organizations/curepsp)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Alzheimer Europe](/institutions/alzheimer-europe)

References